Treatment of HCV infection with pegylated interferons

National Institute of Health Consensus Development Conference Panel statement: management of hepatitis C [no authors listed]. Hepatology 1997, 26:2S–10S.

Seeff LB, Buskell-Bates Z, Wright EC, et al.: Long-term mortality after transfusion-associated non-A non-B hepatitis. N Engl J Med. 1992, 327:1906–1911.

Seeff LB: Natural history of hepatitis C. Hepatology. 1997, 26:21S-28S.

Hoofnagle JH: Hepatitis C: the clinical spectrum of disease. Hepatology. 1997, 26:15S-20S.

Di Bisceglie AM: Natural history of hepatitis C: its impact on clinical management. Hepatology. 2000, 31:1014–1018.

Seeff LB, Hollinger B, Alter AJ, et al.: Long-term morbidity of post transfusion hepatitis C. Hepatology. 1998, 28:407A.

Fattovich G, Guistina G, Degos F, et al.: Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997, 112:463–472.

Serfaty L, Aumaitre H, Chazouileres O, et al.: Determinants of outcome of compensated hepatitis C virus related cirrhosis. Hepatology. 1998, 27:1435–1440.

Yano M, Kumada H, Kage M, et al.: The long-term pathological evolution of chronic hepatitis C. Hepatology. 1996, 23:1334–1340.

Poynard T, Bedossa P, Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. 1997, 349:825–832.

Lindsay KL: Therapy of chronic hepatitis C: overview. Hepatology. 1997, 26(suppl):71S-77S.

Craxi A, Almasio P, Schalm S: Evaluation of efficacy of antiviral therapy for chronic hepatitis C: a EUROHEP Consensus Report on response criteria. J Viral Hepat. 1996, 3:273–276.

Craxi A, Camma C, Guinta M: Definition of response. Paper presented at the EASL International Consensus Conference on Hepatitis C (suppl). Paris, France; February 26–28, 1999.

Booth JCL: Current clinical practise guidelines on the management of HCV. In The Effective Management of Hepatitis C Infection, edn 2. Edited by Bossendine M, et al. London: Aesculapius Press; 2003:55–74.

Angelini G, Sgarbi D, Colombari R, et al.: Alpha-interferon treatment of chronic hepatitis C: a controlled, multi-centre, prospective study. Digestion. 1995, 56:199–203.

Poynard T, Bedossa P, Chevallier M, et al.: A comparison of three interferon alpha 2b regimens for long term treatment of chronic non-A, non-B hepatitis. N Engl J Med. 1995, 332:1457–1462.

Reichard O, Foberg U, Fryden A, et al.: High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon alpha 2b for 60 weeks. Hepatology. 1994, 19:280–285.

Tsubota A, Chayama K, Ikeda K, et al.: Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology. 1994, 19:1088–1094.

Martinot-Peignoux M, Marcellin P, Pouteau M, et al.: Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alpha therapy in chronic hepatitis C. Hepatology. 1995, 22:1050–1056.

McHutchinson JG, Gordon ST, Schiff ER, et al.: Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. The Hepatitis Interventional Therapy Group. N Engl J Med. 1998, 339:1485–1492.

Poynard T, Marcellin P, Lee S, et al.: Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 1998, 352:1426–1432.

Brillianti S, Garson J, Foli M, et al.: A pilot study of combination therapy with ribavirin plus interferon alpha for interferon alpha resistant chronic hepatitis C. Gastroenterology 1994, 107:812–817.

Davis GL, Mur RE, Rustgi V, et al.: Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. The Hepatitis Interventional Therapy Group. N Engl J Med. 1998, 339:1493–1499.

Wills RJ: Clinical pharmacokinetics of interferons. Clin Pharmacokinet. 1990, 19:390–399.

Xu ZX, Patel I, Joubert P: Single dose safety/tolerability and pharmacokinetics/pharmacodynamics following ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon alpha-2a (IFN alpha-2a) to healthy subjects [abstract]. Hepatology. 1998, 28(suppl):702.

Reddy KR: Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. Ann Pharmacother. 2000, 34:915–923.

Glue P, Fang JW, Rouzier-Panis R, et al.: Pegylated interferon alpha-2b: pharmacokinetics, pharmacokinetics, pharmacodynamics, safety and preliminary efficacy. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther. 2000, 68:556–567.

Modi M, Fried M, Reindollar R, et al.: The pharmacokinetics behaviour of pegylated (40 kDa) interferon alfa 2a (PEGASYS) in chronic hepatitis C infection after multiple dosing. Paper presented at the 51st Annual Meeting of the American Association for the Study of Liver Diseases. Dallas, TX; October 27–31, 2000.

Lindsay K, Trepo C, Heintges T, et al.: Randomised, doubleblind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001, 34:395–403.

Zeuzem S, Feinman SV, Rasenack J, et al.: Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000, 343:1666–1672.

Heathcote EJ, Shiffman ML, Cooksley WG, et al.: Peginterferon alpha-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000, 343:1673–1680.

Manns MP, McHutchinson J, Gordon SC, et al.: Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b as initial treatment for chronic hepatitis C: a randomised trial. Lancet. 2001, 358:958–965. Pivotal trial of peginterferon alfa-2b.

Fried MW, Shiffman ML, Reddy KR, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C infection. N Engl J Med 2002, 347:975–982. Pivotal trial of peginterferon alfa-2a.

Hadziyannis SJ, Sette H, Morgan TR, et al.: Peginterferon alpha-2a (40 kilodaltons) and ribavirin combination therapy in chronic hepatitis C: randomised study of the effect of treatment duration and ribavirin dosage. Ann Intern Med 2004, 140:346–355. Randomised trial examining different dosing regimens for peginterferon alfa-2a and ribavirin.

Davis GL: Monitoring of viral levels during therapy of hepatitis C. Hepatology. 2002, 36(suppl):S145-S151.

Hoofnagle JH, Di Bisceglie AM: The treatment of chronic viral hepatitis. N Engl J Med. 1997, 336:347–356.

EASL International Consensus Conference on Hepatitis C. Consensus statement [no authors listed]. J Hepatol 1999, 30:956–961.

Booth JCL, O’Grady J, Neuberger J: Clinical guidelines on the management of hepatitis C. Gut. 2001, 49(suppl):1–21.

Stradler DB, Wright T, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C. AASLD Practice Guidelines. Hepatology. 2004, 39:1147–1171. Up-to-date evidence-based guidelines.

Zeuzem S, Diago M, Gane E, et al.: Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with hepatitis C and normal aminotransferase levels. Gastroenterology. 2004, 127:1724–1732.

Jaekel E, Cornberg M, Wedemeyer H, et al.: Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001, 345:1452–1457.

Gerlach JT, Diepolder HM, Zachoval R, et al.: Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003, 125:80–88.